FDA Approves New Combination Therapy for Follicular Lymphoma and Marginal Zone Lymphoma

The U.S. Food and Drug Administration (FDA) recently approved Revlimid® (lenalidomide) in combination with Rituxan® (rituximab) for the treatment of previously treated follicular lymphoma and marginal zone lymphoma. This combination represents a chemotherapy-free option for people who have previously undergone treatment for these two types of non-Hodgkin lymphoma.¹

Approval based on research

This new combination approval was based on results of the two phase III studies AUGMENT and MAGNIFY. The AUGMENT trial included participants with relapsed or refractory follicular lymphoma or marginal zone lymphoma. Participants received either lenalidomide plus rituximab or rituximab plus placebo. In MAGNIFY, participants had either relapsed or refractory follicular lymphoma, marginal zone lymphoma, or mantle cell lymphoma and received induction cycles of lenalidomide and rituximab. The combination therapy was found to reduce the risk of disease progression, measured by progression-free survival, which is defined as the length of time during and after treatment that a patient lives with a disease but it does not get worse.¹